Welcome to our dedicated page for Sanara Medtech news (Ticker: SMTI), a resource for investors and traders seeking the latest updates and insights on Sanara Medtech stock.
Sanara MedTech Inc. (Nasdaq: SMTI) is a medical technology company that regularly issues news and updates about its surgical, chronic wound and skin-focused business. Company announcements describe a portfolio of surgical tissue repair and advanced wound care products, including CellerateRX® Surgical Activated Collagen® Powder, BIASURGE® Advanced Surgical Solution, FORTIFY TRG® Tissue Repair Graft, FORTIFY FLOWABLE® Extracellular Matrix and several biologic bone and soft tissue matrices.
News releases often cover developments in Sanara’s commercial strategy and product adoption. For example, the company has reported on growth in soft tissue repair product sales driven by increased demand for CellerateRX Surgical and BIASURGE, expansion into additional medical facilities and the development of an independent distribution network in U.S. markets. Updates also include information on contracts and partnerships, such as an Innovative Technology contract from Vizient® Inc. for BIASURGE, which provides Vizient’s healthcare facility customers with access to the product at contracted pricing and pre-negotiated terms.
Sanara’s news flow includes financial result announcements, where it discusses segment performance, revenue trends and the impact of its strategic realignment. The company has reported the discontinuation of its Tissue Health Plus (THP) operations and the classification of THP as discontinued operations, emphasizing a renewed focus on its core surgical business. Management commentary in these releases outlines priorities related to operating efficiency and capital allocation toward surgical products.
In addition, Sanara issues updates on its product pipeline and alliances, such as its exclusive U.S. license and distribution agreement for OsStic™ Synthetic Injectable Structural Bio-Adhesive and related internal fixation technology. Investors and observers can use the SMTI news page to follow product-related announcements, financial disclosures, strategic decisions and conference participation updates that the company provides through press releases.
Sanara MedTech (Nasdaq: SMTI) reported fourth-quarter and full-year 2025 results and reaffirmed 2026 guidance. Full-year net revenue rose 19% to $103.1M, Adjusted EBITDA was $17.0M, and the company reaffirmed 2026 revenue guidance of $116M–$121M (≈13%–17% growth).
Management highlighted commercial expansion, Vizient Innovative Technology contracting for BIASURGE, planned U.S. launch of OsStic in 1Q2027 pending FDA clearance, and increased R&D investment.
Sanara MedTech (Nasdaq: SMTI) announced publication of a peer-reviewed Journal of Medical Economics study (March 11, 2026) evaluating CellerateRX Surgical Powder for high-risk spine surgery wounds. The one-year economic model (2025 USD) found $3,852 cost savings, a 0.007 QALY gain, and a $4,542 net monetary benefit per patient; readmissions and revisions accounted for $2,238 and $835 of savings. Probabilistic analysis showed dominance in >99% of simulations.
Sanara MedTech (Nasdaq: SMTI) will report its fourth quarter and full year 2025 financial results on March 24, 2026 before U.S. markets open. The company will host a conference call and webcast on March 24, 2026 at 8:00 a.m. ET to discuss results for the quarter and year ended December 31, 2025 and answer questions.
Dial-in details, replay instructions, and a live webcast link are provided; an online replay will be available for approximately one year.
Sanara MedTech (Nasdaq: SMTI) will present at the TD Cowen 46th Annual Health Care Conference in Boston. Management is scheduled to deliver a presentation on Tuesday, March 3, 2026 at approximately 9:10 a.m. ET.
Presentation materials and a live audio webcast will be posted to the company’s Investor Relations website prior to the presentation, and an archived replay will be available after the conference.
Sanara MedTech (Nasdaq: SMTI) reported unaudited preliminary results for Q4 and full-year 2025 and issued full-year 2026 guidance. Q4 2025 revenue is expected to be $27.2M–$27.7M (up ~3%–5%; or +11%–13% ex-$1.8M BIASURGE 2024 sales). FY 2025 revenue is expected at $102.7M–$103.2M (≈19% growth; ≈21%–22% ex the $1.8M item). Cash was ≈$16.6M and long-term debt ≈$46.0M at 12/31/2025. Operational highlights include a Vizient Innovative Technology contract for BIASURGE and continued work with Biomimetic Innovations on OsStic, targeted for U.S. commercial introduction in Q1 2027 pending FDA clearance. 2026 revenue guidance is $116M–$121M (+13%–17% vs 2025 midpoint). The results remain unaudited and subject to final audit adjustments.
Sanara MedTech (Nasdaq: SMTI) announced that its BIASURGE® Advanced Surgical Solution received an Innovative Technology contract from Vizient, effective January 1, 2026. The contract followed recommendation by Vizient client-led hospital councils and provides Vizient members access to BIASURGE at pre-negotiated pricing and contracted terms. Vizient represents a broad client base with a portfolio exceeding $156 billion in annual purchasing volume. The company highlighted BIASURGE’s no-rinse irrigation and antimicrobial preservative as clinical differentiators and said it will engage Vizient clients to introduce the product and educate on surgical wound treatment potential.
Sanara MedTech (Nasdaq: SMTI) and Biomimetic Innovations provided a progress update on OsStic™, a synthetic injectable structural bio-adhesive targeted for U.S. commercial launch in Q1 2027, conditional on anticipated FDA clearance. OsStic received FDA Breakthrough Device Designation (Dec 2023) and a U.S. patent was granted in 2025 (U.S. Patent No. 12,251,490) covering compositions, adhesives, kits, and prefilled syringes. The release cites preclinical mechanical testing showing 40x stronger bonding versus traditional calcium phosphate bone cement and notes ongoing product development, clinical, regulatory, and medical education milestones in 2025.
Sanara MedTech (Nasdaq: SMTI) said company management will present at the Piper Sandler 37th Annual Healthcare Conference in New York, running December 2–4, 2025. Management will deliver a presentation to investors on Wednesday, December 3 at ~9:30 a.m. Eastern Time. Presentation materials will be posted to the company’s investor relations website prior to the talk. A live audio webcast will be accessible under the Events section of the investor relations site, and an archive will be available for replay after the conference.
Sanara MedTech (Nasdaq: SMTI) reported third quarter 2025 results: Q3 net revenue $26.3M (+22% YoY) and YTD net revenue $75.6M (+25% YoY). Q3 adjusted EBITDA was $4.9M versus $2.6M a year ago; YTD adjusted EBITDA was $12.3M versus $5.1M. Net income from continuing operations was $0.8M in Q3 and $0.7M YTD. Gross margin improved to 93% in Q3. The company classified Tissue Health Plus (THP) as discontinued operations and recorded a $26.5M noncash impairment, contributing to Q3 discontinued losses of $31.2M and YTD discontinued losses of $36.7M. Cash was $14.9M and long-term debt $45.1M as of September 30, 2025.
Sanara MedTech (Nasdaq: SMTI) completed its evaluation of strategic alternatives for the Tissue Health Plus (THP) segment and has initiated a strategic realignment to discontinue THP operations and focus on its core surgical business.
The company ceased THP development in late September, will classify THP as discontinued operations under US GAAP, expects the wind‑down to continue through end of 2025, and projects $5.5M–$6.5M total cash investment in THP in the second half of 2025, with no material THP cash expenses expected after year‑end.